Institute of Clinical Neurosciences, Carlos Haya Regional University Hospital, Avenida Carlos Haya s/n, 29010 Málaga, Spain.
J Neurol. 2012 Sep;259(9):1814-23. doi: 10.1007/s00415-012-6414-9.
Natalizumab has been shown to be effective in pivotal clinical trials in multiple sclerosis; however, the patients in whom treatment is indicated in clinical practice have a different clinical profile from those included in the clinical trials. The aim of this study is therefore to collect data on natalizumab use in everyday clinical practice in Spain. The 86 participating centers throughout Spain submitted data on disease characteristics at baseline and after treatment. Valid data were available for 1,364 patients (69.3% women, 86.9% with relapsing–remitting disease).
那他珠单抗在多发性硬化症的关键性临床试验中已被证实有效；然而，在临床实践中需要接受治疗的患者与临床试验中纳入的患者具有不同的临床特征。因此，本研究旨在收集西班牙日常临床实践中使用那他珠单抗的数据。西班牙的 86 个参与中心提交了基线时和治疗后疾病特征的数据。共有 1364 名患者（69.3%为女性，86.9%为复发缓解型疾病）的有效数据可用。
